Qing Che Zuraw - 17 Jul 2025 Form 4 Insider Report for Vor Biopharma Inc. (VOR)

Role: Chief Development Officer
Signature: /s/ Sherell Bacchas, Attorney-in-Fact
Issuer symbol: VOR
Transactions as of: 17 Jul 2025
Transactions value $: $0
Form type: 4
Filing time: 30 Jul 2025, 16:03:38 UTC
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Zuraw Qing Che	Chief Development Officer	C/O VOR BIOPHARMA INC., 100 CAMBRIDGEPARK DRIVE, SUITE 101, CAMBRIDGE	/s/ Sherell Bacchas, Attorney-in-Fact	30 Jul 2025	0002079210

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	VOR	Common Stock	Award	$0	+937K		$0.00	937K	17 Jul 2025	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	VOR	Employee Stock Option (right to buy)	Award	$0	+4.37M		$0.00	4.37M	17 Jul 2025	Common Stock	4.37M	$2.38	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents the number of shares underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of common stock of the Issuer. 1/4th of the RSUs vest on August 1, 2026, with the remainder vesting in substantially equal quarterly installments over 3 years, in each case subject to the Reporting Person's continued service as of each such date.
F2	1/4th of the shares underlying the option vest on July 17, 2026, with the remainder vesting in substantially equal monthly installments over 3 years, in each case subject to the Reporting Person's continued service as of each such date.